Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets

Sean A. Hudson, Kirsty J. McLean, Andrew W. Munro, Chris Abell

    Research output: Contribution to journalArticlepeer-review


    TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability. ©The Authors Journal compilation ©2012 Biochemical Society.
    Original languageEnglish
    Pages (from-to)573-579
    Number of pages6
    JournalBiochemical Society Transactions
    Issue number3
    Publication statusPublished - Jun 2012


    • Cytochrome P450
    • Drug discovery
    • Fragment-based drug discovery
    • High-throughput screening (HTS)
    • Mycobacterium tuberculosis
    • Tuberculosis


    Dive into the research topics of 'Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets'. Together they form a unique fingerprint.

    Cite this